BioCardia Inc. (BCDA)
BCDA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/0001437749-26-009587-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BCDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000925741 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$8.2M |
| Operating income | -$8.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $2.5M |
| Total assets | $3.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $2.2M cash; operating cash flow -$1.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 15,138,782 (2026-11-11); 10,612,734 a year earlier; 21,619,432 three years earlier. 3y figure adjusted for splits (1-for-15 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2024-05-30 | Source 2024-05-30 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-21 |
| Auditor | PKF San Diego, LLP, San Diego, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $169K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$1.8M | -$1.7M | $2.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$1.6M | -$1.7M | $4.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$2.3M | -$1.7M | $951K | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | $0 | -$2.0M | -$2.5M | $2.5M | No debt tags | $0 | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | $0 | -$1.5M | -$1.7M | $5.3M | No debt tags | $0 | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$2.0M | -$1.6M | $980K | No debt tags | $0 | 10-Q/A 2025-10-29 |
| Q1 2025 2025-03-31 | $0 | -$2.7M | -$1.6M | $949K | No debt tags | $3K | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | $0 | -$2.3M | -$2.4M | $2.4M | No debt tags | $58K | 10-K 2026-03-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2025-10-24 |
| Latest annual report FORM 10-K | 10-K | 2026-03-24 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy FORM DEF 14A | DEF 14A | 2025-11-03 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.4% |
| 1 month | -16.2% |
| 3 months | -10.8% |
| Year to date | -33.6% |
| 1 year | -34.1% |
| From 52-week high | -43.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
| ATYR | aTyr Pharma Inc. | $5.24 | -14.17% | $13.4M |
| SCLX | Scilex Holding Company | $1.25 | -12.59% | $10.6M |
| ALGS | Aligos Therapeutics Inc. | $1.66 | -20.95% | $10.4M |
| INTS | Intensity Therapeutics Inc. | $3.07 | -0.32% | $10.1M |
| PLUR | Pluri Inc. | $1.04 | -0.95% | $15.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier